Search research articles
Contact Us
Filters
Showing results (251-260 of 270) with videos related to
Page
of 27
Sort By:
Vaccine
|
May 24, 2020
Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya
M Oneko, Y R Cherop, T Sang, et al.
PLOS Global Public Health
|
June 26, 2025
Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya) - Effect of ATSBs on epidemiologic and entomologic indicators: A Phase III, open-label, cluster-randomised, controlled trial
Caroline Ogwang, Aaron M Samuels, Daniel P McDermott, et al.
The Lancet. Global Health
|
September 20, 2025
Sustained efficacy of the RTS,S/AS01<sub>E</sub> malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
Lawrence Osei-Tutu, Simon K Kariuki, Cynthia K Lee, et al.
Emerging Infectious Diseases
|
November 21, 2017
Capacity Development through the US President's Malaria Initiative-Supported Antimalarial Resistance Monitoring in Africa Network
Eric S Halsey, Meera Venkatesan, Mateusz M Plucinski, et al.
The Journal of Infectious Diseases
|
March 4, 2024
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
Nelli Westercamp, Lawrence Osei-Tutu, Lode Schuerman, et al.
Emerging Infectious Diseases
|
June 21, 2021
Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018
Sarah E Schmedes, Dhruviben Patel, Simran Dhal, et al.
Lancet (London, England)
|
April 7, 2024
Feasibility, safety, and impact of the RTS,S/AS01<sub>E</sub> malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
Kwaku Poku Asante, Don P Mathanga, Paul Milligan, et al.
The Lancet. Infectious Diseases
|
June 26, 2022
Efficacy of RTS,S/AS01<sub>E</sub> malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
Aaron M Samuels, Daniel Ansong, Simon K Kariuki, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 27, 2019
Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya
Laura C Steinhardt, Thomas L Richie, Reuben Yego, et al.
Nature Medicine
|
September 14, 2021
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
Martina Oneko, Laura C Steinhardt, Reuben Yego, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 270) with videos related to
Sort By:
Page
of 27
Vaccine
|
May 24, 2020
Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya
M Oneko, Y R Cherop, T Sang, et al.
PLOS Global Public Health
|
June 26, 2025
Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya) - Effect of ATSBs on epidemiologic and entomologic indicators: A Phase III, open-label, cluster-randomised, controlled trial
Caroline Ogwang, Aaron M Samuels, Daniel P McDermott, et al.
The Lancet. Global Health
|
September 20, 2025
Sustained efficacy of the RTS,S/AS01<sub>E</sub> malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
Lawrence Osei-Tutu, Simon K Kariuki, Cynthia K Lee, et al.
Emerging Infectious Diseases
|
November 21, 2017
Capacity Development through the US President's Malaria Initiative-Supported Antimalarial Resistance Monitoring in Africa Network
Eric S Halsey, Meera Venkatesan, Mateusz M Plucinski, et al.
The Journal of Infectious Diseases
|
March 4, 2024
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
Nelli Westercamp, Lawrence Osei-Tutu, Lode Schuerman, et al.
Emerging Infectious Diseases
|
June 21, 2021
Plasmodium falciparum kelch 13 Mutations, 9 Countries in Africa, 2014-2018
Sarah E Schmedes, Dhruviben Patel, Simran Dhal, et al.
Lancet (London, England)
|
April 7, 2024
Feasibility, safety, and impact of the RTS,S/AS01<sub>E</sub> malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
Kwaku Poku Asante, Don P Mathanga, Paul Milligan, et al.
The Lancet. Infectious Diseases
|
June 26, 2022
Efficacy of RTS,S/AS01<sub>E</sub> malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
Aaron M Samuels, Daniel Ansong, Simon K Kariuki, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 27, 2019
Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya
Laura C Steinhardt, Thomas L Richie, Reuben Yego, et al.
Nature Medicine
|
September 14, 2021
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
Martina Oneko, Laura C Steinhardt, Reuben Yego, et al.
Page
of 27